PPAR alpha + Hydrochlorothiazide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Hypertension
Conditions
Mild Hypertension
Trial Timeline
Sep 1, 2006 → Nov 1, 2006
NCT ID
NCT00374855About PPAR alpha + Hydrochlorothiazide + Placebo
PPAR alpha + Hydrochlorothiazide + Placebo is a phase 2 stage product being developed by Eli Lilly for Mild Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00374855. Target conditions include Mild Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00374855 | Phase 2 | Completed |
Competing Products
20 competing products in Mild Hypertension